B-intervention	0	10	Supervised
I-intervention	11	17	versus
I-intervention	18	28	autonomous
I-intervention	29	37	exercise
I-intervention	38	46	training
O	47	49	in
O	50	56	breast
O	57	63	cancer
O	64	72	patients
O	72	73	:
O	74	75	A
O	76	87	multicenter
O	88	98	randomized
O	99	107	clinical
O	108	113	trial
O	113	114	.

O	115	120	There
O	121	123	is
O	124	125	a
O	126	130	well
O	130	131	-
O	131	136	known
O	137	148	correlation
O	149	156	between
O	157	164	obesity
O	164	165	,
O	166	175	sedentary
O	176	185	lifestyle
O	185	186	,
O	187	190	and
O	191	197	breast
O	198	204	cancer
O	205	214	incidence
O	215	218	and
O	219	226	outcome
O	226	227	.

O	228	231	The
O	232	251	Arbeitsgemeinschaft
O	252	262	Medikament
O	262	263	ö
O	263	265	se
O	266	279	Tumortherapie
O	280	281	(
O	281	285	AGMT
O	285	286	)
O	287	295	exercise
O	296	301	study
O	302	305	was
O	306	307	a
O	308	319	multicenter
O	319	320	,
O	321	331	randomized
O	332	340	clinical
O	341	346	trial
O	347	350	and
O	351	359	assessed
O	360	363	the
O	364	375	feasibility
O	376	379	and
O	380	388	efficacy
O	389	391	of
O	392	400	physical
O	401	409	training
O	410	412	in
B-total-participants	413	415	50
B-eligibility	416	422	breast
I-eligibility	423	429	cancer
I-eligibility	430	438	patients
I-eligibility	439	449	undergoing
I-eligibility	450	459	aromatase
I-eligibility	460	469	inhibitor
I-eligibility	470	479	treatment
O	479	480	.

B-eligibility	481	495	Postmenopausal
I-eligibility	495	496	,
I-eligibility	497	505	estrogen
I-eligibility	506	514	receptor
I-eligibility	514	515	-
I-eligibility	515	523	positive
I-eligibility	524	530	breast
I-eligibility	531	537	cancer
I-eligibility	538	546	patients
I-eligibility	547	552	under
I-eligibility	553	562	aromatase
I-eligibility	563	572	inhibitor
I-eligibility	573	582	treatment
O	583	587	were
O	588	598	randomized
O	599	600	1
O	600	601	:
O	601	602	1
O	603	605	to
O	606	616	counseling
O	617	620	and
O	621	633	unsupervised
O	634	642	training
O	643	646	for
O	647	649	48
O	650	655	weeks
O	656	657	(
B-control	657	669	unsupervised
I-control	670	673	arm
O	673	674	)
O	675	677	or
O	678	688	counseling
O	689	692	and
O	693	694	a
O	695	705	sequential
O	706	714	training
O	715	716	(
O	716	726	supervised
O	727	730	arm
O	730	731	)
O	732	736	with
O	737	738	a
O	739	749	supervised
O	750	755	phase
O	756	757	(
O	757	759	24
O	760	765	weeks
O	765	766	)
O	767	775	followed
O	776	778	by
O	779	791	unsupervised
O	792	800	physical
O	801	809	training
O	810	811	(
O	811	818	further
O	819	821	24
O	822	827	weeks
O	827	828	)
O	828	829	.

O	830	837	Primary
O	838	846	endpoint
O	847	850	was
O	851	854	the
B-outcome-Measure	855	865	individual
I-outcome-Measure	866	873	maximum
I-outcome-Measure	874	879	power
I-outcome-Measure	880	886	output
I-outcome-Measure	887	889	on
I-outcome-Measure	890	891	a
I-outcome-Measure	892	897	cycle
I-outcome-Measure	898	907	ergometer
I-outcome-Measure	908	913	after
I-outcome-Measure	914	916	24
I-outcome-Measure	917	922	weeks
I-outcome-Measure	923	925	of
I-outcome-Measure	926	934	exercise
O	934	935	.

O	936	937	A
O	938	941	key
O	942	951	secondary
O	952	960	endpoint
O	961	964	was
O	965	968	the
B-outcome-Measure	969	980	feasibility
I-outcome-Measure	981	983	of
I-outcome-Measure	984	993	achieving
I-outcome-Measure	994	996	12
I-outcome-Measure	997	1001	METh
I-outcome-Measure	1001	1002	/
I-outcome-Measure	1002	1006	week
I-outcome-Measure	1007	1008	(
I-outcome-Measure	1008	1017	metabolic
I-outcome-Measure	1018	1028	equivalent
I-outcome-Measure	1029	1031	of
I-outcome-Measure	1032	1036	task
I-outcome-Measure	1037	1042	hours
I-outcome-Measure	1043	1046	per
I-outcome-Measure	1047	1051	week
I-outcome-Measure	1051	1052	)
O	1052	1053	.

B-control-participants	1054	1060	Twenty
I-control-participants	1060	1061	-
I-control-participants	1061	1066	three
O	1067	1075	patients
O	1076	1077	(
O	1077	1079	92
O	1079	1080	%
O	1080	1081	)
O	1082	1084	in
O	1085	1088	the
O	1089	1101	unsupervised
O	1102	1105	arm
O	1106	1109	and
B-intervention-participants	1110	1112	19
O	1113	1121	patients
O	1122	1123	(
O	1123	1125	76
O	1125	1126	%
O	1126	1127	)
O	1128	1130	in
O	1131	1134	the
O	1135	1145	supervised
O	1146	1149	arm
O	1150	1154	with
O	1155	1160	early
O	1160	1161	-
O	1161	1166	stage
O	1167	1173	breast
O	1174	1180	cancer
O	1181	1190	completed
O	1191	1194	the
O	1195	1200	study
O	1200	1201	.

B-outcome	1202	1207	After
I-outcome	1208	1210	24
I-outcome	1211	1216	weeks
O	1216	1217	,
O	1218	1221	the
O	1222	1232	supervised
O	1233	1236	arm
O	1237	1245	achieved
O	1246	1247	a
O	1248	1261	significantly
O	1262	1268	higher
B-outcome	1269	1276	maximum
I-outcome	1277	1283	output
I-outcome	1284	1286	in
I-outcome	1287	1291	watt
O	1292	1293	(
O	1293	1297	mean
B-iv-cont-mean	1298	1301	132
O	1302	1303	±
O	1305	1313	standard
O	1314	1323	deviation
O	1324	1325	[
O	1325	1327	SD
O	1327	1328	]
B-iv-cont-sd	1329	1331	34
O	1331	1332	;
O	1333	1335	95
O	1335	1336	%
O	1337	1347	confidence
O	1348	1356	interval
O	1357	1358	[
O	1358	1360	CI
O	1360	1361	]
O	1362	1365	117
O	1365	1366	-
O	1366	1369	147
O	1369	1370	)
O	1371	1379	compared
O	1380	1382	to
O	1383	1391	baseline
O	1392	1393	(
O	1393	1396	107
O	1397	1398	±
O	1399	1401	25
O	1401	1402	;
O	1403	1405	95
O	1405	1406	%
O	1406	1408	CI
O	1409	1411	97
O	1411	1412	-
O	1412	1415	117
O	1415	1416	;
O	1417	1418	P
O	1419	1420	=
O	1421	1422	0
O	1422	1423	.
O	1423	1426	012
O	1426	1427	)
O	1428	1432	with
O	1433	1434	a
O	1435	1446	numerically
O	1447	1453	higher
O	1454	1460	output
O	1461	1465	than
O	1466	1469	the
O	1470	1482	unsupervised
O	1483	1486	arm
O	1487	1488	(
O	1488	1492	week
O	1493	1495	24
B-cv-cont-mean	1496	1499	115
O	1500	1501	±
B-cv-cont-sd	1502	1504	25
O	1504	1505	;
O	1506	1508	95
O	1508	1509	%
O	1509	1511	CI
O	1512	1515	105
O	1515	1516	-
O	1516	1519	125
O	1519	1520	;
O	1521	1522	P
O	1523	1524	=
O	1525	1526	0
O	1526	1527	.
O	1527	1530	059
O	1530	1531	)
O	1531	1532	.

O	1533	1546	Significantly
O	1547	1553	higher
B-outcome	1554	1558	METh
I-outcome	1558	1559	/
I-outcome	1559	1563	week
O	1564	1567	was
O	1568	1576	reported
O	1577	1579	in
O	1580	1583	the
O	1584	1594	supervised
O	1595	1598	arm
O	1599	1607	compared
O	1608	1610	to
O	1611	1614	the
O	1615	1627	unsupervised
O	1628	1631	arm
O	1632	1638	during
O	1639	1642	the
O	1643	1648	whole
O	1649	1654	study
O	1655	1661	period
O	1662	1663	(
B-outcome	1663	1667	week
I-outcome	1668	1669	1
I-outcome	1669	1670	-
I-outcome	1670	1672	24
O	1673	1685	unsupervised
O	1685	1686	:
B-cv-cont-mean	1687	1689	18
I-cv-cont-mean	1689	1690	.
I-cv-cont-mean	1690	1691	3
O	1692	1693	(
O	1693	1694	7
O	1694	1695	.
O	1695	1696	6
O	1696	1697	-
O	1697	1699	58
O	1699	1700	.
O	1700	1701	3
O	1701	1702	)
O	1702	1703	;
O	1704	1714	supervised
O	1714	1715	:
B-iv-cont-mean	1716	1718	28
I-iv-cont-mean	1718	1719	.
I-iv-cont-mean	1719	1720	5
O	1721	1722	(
O	1722	1723	6
O	1723	1724	.
O	1724	1725	7
O	1725	1726	-
O	1726	1728	40
O	1728	1729	.
O	1729	1730	1
O	1730	1731	)
O	1731	1732	;
O	1733	1734	P
O	1735	1736	=
O	1737	1738	0
O	1738	1739	.
O	1739	1742	043
O	1742	1743	;
O	1744	1748	week
O	1749	1751	25
O	1751	1752	-
O	1752	1754	48
O	1754	1755	;
O	1756	1757	P
O	1758	1759	=
O	1760	1761	0
O	1761	1762	.
O	1762	1765	041
O	1765	1766	)
O	1766	1767	)
O	1767	1768	.

O	1769	1773	This
O	1774	1779	trial
O	1780	1789	indicates
O	1790	1794	that
O	1795	1803	patients
O	1804	1806	in
O	1807	1809	an
O	1810	1818	exercise
O	1819	1826	program
O	1827	1834	achieve
O	1835	1841	higher
O	1842	1849	fitness
O	1850	1856	levels
O	1857	1863	during
O	1864	1874	supervised
O	1875	1879	than
O	1880	1892	unsupervised
O	1893	1901	training
O	1901	1902	.
